• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Effect of 5-aminosalicylic acid (5-ASA) and other salicylates on short-chain fat metabolism in the colonic mucosa. Pharmacological implications for ulcerative colitis.

作者信息

Roediger W, Schapel G, Lawson M, Radcliffe B, Nance S

出版信息

Biochem Pharmacol. 1986 Jan 15;35(2):221-5. doi: 10.1016/0006-2952(86)90517-4.

DOI:10.1016/0006-2952(86)90517-4
PMID:2867767
Abstract

5-Aminosalicylic acid (5-ASA) suppressed nitrite-stimulated oxidation of the fatty acid n-butyrate in a dose-dependent manner in isolated human and rat colonic epithelial cells. 4-ASA had one-sixth of the capacity of 5-ASA and sulphapyridine (SP) little of the capacity of 5-ASA to suppress fatty acid oxidation in human colonic epithelial cells. Sulphasalazine (SASP), azodisalicylic acid (ADS), acetyl-5-ASA and acetyl salicylic acid (ASA) did not suppress fatty acid oxidation in rat colonocytes. The suppression index of fatty acid oxidation (SIFO) of respective salicylic acids correlated with the reported clinical effectiveness of each drug against ulcerative colitis (UC). The capacity of 5-ASA to affect nitrite-stimulated oxidation of fat in the colonic mucosa suggests that nitrite ions and control of fatty acid oxidation play a central role in the development and therapy of active UC.

摘要

相似文献

1
Effect of 5-aminosalicylic acid (5-ASA) and other salicylates on short-chain fat metabolism in the colonic mucosa. Pharmacological implications for ulcerative colitis.
Biochem Pharmacol. 1986 Jan 15;35(2):221-5. doi: 10.1016/0006-2952(86)90517-4.
2
Assessment of salicylate derivatives for potential use in ulcerative colitis: proposal for a new action of 5-aminosalicylic acid?
Pharmacology. 1989;39(1):39-45. doi: 10.1159/000138569.
3
Influence of sulfasalazine, 5-aminosalicylic acid and sulfapyridine on prostanoid synthesis and metabolism in rabbit colonic mucosa.柳氮磺胺吡啶、5-氨基水杨酸和磺胺吡啶对兔结肠黏膜中前列腺素合成及代谢的影响。
Prostaglandins. 1985 Jan;29(1):133-42. doi: 10.1016/0090-6980(85)90158-3.
4
Effect of aminophenols (5-ASA and 4-ASA) on colonic interleukin-1 generation.氨基酚(5-氨基水杨酸和4-氨基水杨酸)对结肠白细胞介素-1生成的影响。
Gut. 1992 Jul;33(7):929-32. doi: 10.1136/gut.33.7.929.
5
Selective inhibition of fatty acid oxidation in colonocytes by ibuprofen: a cause of colitis?布洛芬对结肠细胞脂肪酸氧化的选择性抑制:结肠炎的一个病因?
Gut. 1995 Jan;36(1):55-9. doi: 10.1136/gut.36.1.55.
6
Inhibition of prostaglandin synthetase in human rectal mucosa.人直肠黏膜中前列腺素合成酶的抑制作用。
Gut. 1983 Mar;24(3):213-7. doi: 10.1136/gut.24.3.213.
7
Azodisalicylate (azodisal sodium) causes intestinal secretion. Comparative study of the effect of azodisalicylate, sulfasalazine, 5-aminosalicylic acid and sulfapyridine on the water and electrolyte transfer and the morphology of the rat ileum and colon in vivo.偶氮双水杨酸酯(偶氮双水杨酸钠)可引起肠道分泌。偶氮双水杨酸酯、柳氮磺胺吡啶、5-氨基水杨酸和磺胺吡啶对大鼠回肠和结肠水与电解质转运及形态学影响的比较研究。
Digestion. 1987;37(2):79-87. doi: 10.1159/000199472.
8
Effects of BX661A, a new therapeutic agent for ulcerative colitis, on reactive oxygen species in comparison with salazosulfapyridine and its metabolite sulfapyridine.溃疡性结肠炎新型治疗药物BX661A与柳氮磺胺吡啶及其代谢产物磺胺吡啶相比对活性氧的影响
Arzneimittelforschung. 1998 Oct;48(10):1007-11.
9
Determination of the active moiety of BX661A, a new therapeutic agent for ulcerative colitis, by studying its therapeutic effects on ulcerative colitis induced by dextran sulfate sodium in rats.通过研究BX661A对葡聚糖硫酸钠诱导的大鼠溃疡性结肠炎的治疗效果来确定其活性部分,BX661A是一种用于治疗溃疡性结肠炎的新型治疗药物。
Arzneimittelforschung. 1998 Nov;48(11):1091-6.
10
[Localization of salazopyrin in colonic mucosa patients with ulcerative colitis].[柳氮磺胺吡啶在溃疡性结肠炎患者结肠黏膜中的定位]
Nihon Shokakibyo Gakkai Zasshi. 1993 Feb;90(2):124-33.

引用本文的文献

1
Fatty acids and lipid mediators in inflammatory bowel disease: from mechanism to treatment.炎症性肠病中的脂肪酸和脂质介质:从机制到治疗。
Front Immunol. 2023 Oct 5;14:1286667. doi: 10.3389/fimmu.2023.1286667. eCollection 2023.
2
Effect of a new de-N-acetyl-lysoglycosphingolipid on chemically-induced inflammatory bowel disease: possible mechanism of action.一种新型去N-乙酰赖氨糖鞘脂对化学诱导的炎症性肠病的影响:可能的作用机制。
Naunyn Schmiedebergs Arch Pharmacol. 1993 Dec;348(6):670-8. doi: 10.1007/BF00167246.
3
Possible mode of action of 5-aminosalicylic acid.
5-氨基水杨酸可能的作用方式。
Dig Dis Sci. 1987 Dec;32(12 Suppl):51S-56S. doi: 10.1007/BF01312464.
4
The antiinflammatory moiety of sulfasalazine, 5-aminosalicylic acid, is a radical scavenger.柳氮磺胺吡啶的抗炎部分,5-氨基水杨酸,是一种自由基清除剂。
Agents Actions. 1987 Jun;21(1-2):191-4. doi: 10.1007/BF01974941.
5
Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid.
Dig Dis Sci. 1987 Jun;32(6):577-82. doi: 10.1007/BF01296156.
6
Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease.美沙拉嗪。对其药效学和药代动力学特性以及在慢性炎症性肠病中的治疗潜力的综述。
Drugs. 1989 Oct;38(4):500-23. doi: 10.2165/00003495-198938040-00003.
7
Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease.
Drugs. 1991 Apr;41(4):647-64. doi: 10.2165/00003495-199141040-00009.